← Back to patent-cliff list
Fasudil (Raya Therapeutic)
Tier C — Watch / tradeFasudil (Raya Therapeutic)
University Medical Center Gottingen
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ROCK1, ROCK2, PKC
Indications (approved)：Amyotrophic lateral sclerosis
Regional status
US
-
EU
Phase II
2019-02-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fasudil (Raya Therapeutic)?
Approved indications include: Amyotrophic lateral sclerosis.
When does the Fasudil (Raya Therapeutic) patent expire?
No public expiry year is available for Fasudil (Raya Therapeutic) yet; this page updates once verified.
How do I get a quote for Fasudil (Raya Therapeutic) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08